Group 1 - The company Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations in annual report information disclosure, leading to a significant drop in stock price and investor losses [1] - The CSRC's investigation is linked to the company's early recognition of revenue amounting to 24.54 million yuan in December 2023, which was later corrected as an accounting error, potentially being a key reason for the investigation [1] - The company has restated its financial reports, reducing its 2023 revenue by 24.54 million yuan, which represents 3.4% of the total revenue for that year, impacting investor decision-making [1] Group 2 - Investors who purchased shares before September 30, 2025, and sold or held them at a loss after October 1, 2025, are eligible to participate in compensation claims through legal channels [2] - The urgency for affected investors to engage in legal action is emphasized, as the company faces significant challenges [2]

Core Viewpoint - The company, Luqiao Information, is under investigation by the China Securities Regulatory Commission (CSRC) for alleged violations related to financial information disclosure, which may lead to potential compensation claims from affected investors [3]. Group 1: Financial Performance - On October 23, Luqiao Information reported a transaction volume of 171 million yuan, with a net inflow of 15.57 million yuan from major investors [2]. Group 2: Regulatory Issues - On October 14, Luqiao Information received a notice from the CSRC regarding an investigation into its financial reporting practices, specifically for violations of the Securities Law and Administrative Penalty Law of the People's Republic of China [3]. - Affected investors who purchased shares between April 23, 2024, and September 29, 2025, and held them until the market close on September 29, 2025, may be eligible for compensation [3]. Group 3: Corporate Governance - The 2024 Annual General Meeting of Luqiao Information was held on May 30, 2025, with a total of 58.704 million shares represented, accounting for 76.5% of the voting shares [4]. - The meeting approved several key resolutions, including the annual report and the board's work report for 2024 [4]. Group 4: Legal Compliance - Legal experts confirmed that the procedures for convening and conducting the 2024 Annual General Meeting complied with relevant laws and regulations, ensuring the legitimacy of the meeting and its outcomes [5].

Core Viewpoint - The company, Luqiao Information, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations in financial information disclosure, following a significant revision of its financial reports that revealed a drastic reduction in projected profits for 2024 by 84.91% [1][4]. Group 1: Regulatory Actions - The CSRC issued a notice of investigation due to suspected violations in the disclosure of financial information in periodic reports [1]. - Prior to the CSRC's investigation, the Xiamen Securities Regulatory Bureau had already mandated corrective measures due to significant internal control deficiencies related to financial reporting [3][4]. - The company has committed to developing a rectification plan and improving its internal control systems in response to regulatory requirements [4]. Group 2: Financial Reporting Issues - Luqiao Information corrected seven financial reports from the past two years, significantly adjusting its financial data, including a major reduction in net profit for 2024 [3][4]. - The adjustments were made using the retrospective adjustment method, affecting reports for 2023 and 2024, among others [3]. Group 3: Management Changes - The company experienced notable management turnover, with both the chairman and the general manager resigning within a month prior to the investigation [4][5]. - The chairman, Yu Zheng, resigned for personal reasons and held 1.42% of the company's shares, while the general manager, Wei Cong, also resigned but retained a position on the board [5].